Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

1

Colesevelam was evaluated for treating lenalidomide-associated diarrhea in multiple myeloma patients in a phase 2 trial.
2

The trial included 25 patients, with 88% showing improvement in diarrhea symptoms after colesevelam treatment.
3

Colesevelam treatment led to complete resolution of diarrhea in 68% of patients, significantly enhancing their quality of life.
4

Lenalidomide maintenance therapy is effective but often causes diarrhea, impacting treatment adherence and patient well-being.
5

Standard anti-diarrheal medications have limited effectiveness, highlighting the need for alternative treatments like colesevelam.

Blood Cancer Journal

by Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn Rose Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Matthew J. Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi Arisa, Cody J. Peer, William D. Figg, Saad Z. Usmani, Ola Landgren, Alexander M. Lesokhin
September 19, 2024

1